文献速递糖尿病

SLC30A8完全缺失改善人类糖代谢与β细胞功能

Complete loss of SLC30A8 in humans improves glucose metabolism and beta cell function.
PubMed 文献 · Diabetologia · 2025-09-29

基于巴基斯坦基因组资源145,037名参与者的外显子与全基因组测序,分析SLC30A8功能缺失(LoF)变异与2型糖尿病风险的关系,并召回携带者行OGTT。共发现18例敲除者与1024例LoF杂合子,2型糖尿病风险随基因剂量依赖性降低,OGTT显示血糖下降伴胰岛素升高。

要点

  • SLC30A8 LoF杂合子与纯合子2型糖尿病风险低于非携带者,呈基因剂量依赖性保护
  • OGTT显示LoF携带者血糖呈剂量依赖性降低,伴胰岛素升高
  • 葡萄糖刺激胰岛素分泌增高且β细胞功能保留,不依赖BMI

核心结论

  • SLC30A8完全缺失在人类中改善糖代谢与β细胞功能,提示治疗性抑制SLC30A8可能安全有效治疗2型糖尿病。

研究设计与样本

  • 分析巴基斯坦基因组资源(PGR)145,037名参与者的全外显子与全基因组测序数据,评估SLC30A8 LoF变异的表型关联。
  • 对SLC30A8 LoF杂合子、纯合子及其参与家庭成员行召回-by-基因型OGTT分析。

主要发现

  • 鉴定出18例SLC30A8敲除者(含南亚富集变异Gln174Ter纯合子)及1024例LoF变异杂合子。
  • 2型糖尿病风险在LoF杂合子与纯合子中低于非携带者,保护效应呈基因剂量依赖性(ORadditive=0.62;95% CI 0.53, 0.72;p=1.1×10-9;ORrecessive=0.34;95% CI 0.12, 0.93;p=0.04)。
  • 召回-by-基因型OGTT显示血糖呈基因剂量依赖性降低,伴胰岛素升高。

关键数值与推荐

  • 校正胰岛素反应、处置指数与胰岛素敏感性指数提示LoF杂合子与纯合子葡萄糖刺激胰岛素分泌增高、β细胞功能保留,且不依赖BMI。

临床怎么用

  • 提示治疗性抑制SLC30A8(包括完全敲除)可能成为2型糖尿病安全有效的治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Genetic association studies have demonstrated that partial loss of SLC30A8 Function protects against type 2 diabetes in humans. We investigated the impact of complete loss of SLC30A8 Function on type 2 diabetes risk and related phenotypes in humans. METHODS: The Pakistan Genome Resource (PGR), a biobank comprising whole-exome and whole-genome sequences of 145,037 participants, was analysed for phenotypic associations with SLC30A8 loss-of-function (LoF) variants. To follow up on the observations in the PGR, we conducted recall-by-genotype analyses of SLC30A8 LoF heterozygotes and homozygotes, as well as their participating family members, using OGTTs. RESULTS: We identified 18 SLC30A8 knockouts, including homozygotes for a variant enriched in South Asians (Gln174Ter), and 1024 heterozygotes for LoF variants. Type 2 diabetes risk was lower in SLC30A8 LoF heterozygotes and homozygotes relative to non-carriers, and the protective effect strengthens in a gene dose-dependent manner (ORadditive=0.62; 95% CI 0.53, 0.72; p=1.1×10-9; ORrecessive=0.34; 95% CI 0.12, 0.93; p=0.04). OGTTs in recall-by-genotype studies showed a gene dose-dependent reduction in glucose levels, coupled with elevated insulin. CONCLUSIONS/INTERPRETATION: The corrected insulin response, disposition index and insulin sensitivity index in LoF heterozygotes and homozygotes indicated higher glucose-stimulated insulin secretion with preserved beta cell function that was independent of BMI. These data suggest that therapeutic inhibition of SLC30A8, up to and including complete knockout, may treat type 2 diabetes safely and effectively.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lamarche LB, Koch C, Khalid S, et al. Complete loss of SLC30A8 in humans improves glucose metabolism and beta cell function. Diabetologia. 2025. PMID: 41020949. doi:10.1007/s00125-025-06530-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。